Drug developer Repligen Corp. said Monday that a federal court refused to dismiss its claims in patent infringement lawsuit against the drugmaker ImClone Systems Inc.

The company said the U.S. District Court in Massachusetts declined to issue a summary judgment requested by ImClone. In its motion, ImClone had argued that that Repligen’s claims should be dismissed because a patent in question had been exhausted.